The stock of MiMedx Group Inc (NASDAQ:MDXG) is a huge mover today! About 708,195 shares traded hands. MiMedx Group Inc (NASDAQ:MDXG) has declined 4.54% since March 7, 2016 and is downtrending. It has underperformed by 12.13% the S&P500.
The move comes after 5 months positive chart setup for the $1000.00M company. It was reported on Oct, 10 by Barchart.com. We have $15.26 PT which if reached, will make NASDAQ:MDXG worth $670.00 million more.
Analysts await MiMedx Group Inc (NASDAQ:MDXG) to report earnings on November, 3. They expect $0.05 EPS, down 16.67% or $0.01 from last year’s $0.06 per share. MDXG’s profit will be $5.47 million for 45.70 P/E if the $0.05 EPS becomes a reality. After $0.02 actual EPS reported by MiMedx Group Inc for the previous quarter, Wall Street now forecasts 150.00% EPS growth.
MiMedx Group Inc (NASDAQ:MDXG) Ratings Coverage
Out of 5 analysts covering MiMedx Group (NASDAQ:MDXG), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. MiMedx Group has been the topic of 7 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, December 18 by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, July 29 by Needham. The firm has “Buy” rating given on Tuesday, April 19 by Lake Street. Northland Capital upgraded MiMedx Group Inc (NASDAQ:MDXG) on Friday, October 30 to “Outperform” rating. Needham maintained MiMedx Group Inc (NASDAQ:MDXG) rating on Wednesday, October 14. Needham has “Buy” rating and $13 price target. Needham upgraded it to “Strong Buy” rating and $13 target price in Monday, November 16 report. On Wednesday, January 20 the stock rating was maintained by First Analysis with “Overweight”.
According to Zacks Investment Research, “MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in Q2 2016. Its down 0.49, from 1.52 in 2016Q1. The ratio is negative, as 22 funds sold all MiMedx Group Inc shares owned while 49 reduced positions. 21 funds bought stakes while 52 increased positions. They now own 47.18 million shares or 4.50% more from 45.15 million shares in 2016Q1.
Loomis Sayles & Company Lp owns 352 shares or 0% of their US portfolio. Pub Employees Retirement Association Of Colorado reported 24,331 shares or 0% of all its holdings. Raymond James Financial Svcs Inc has 0% invested in the company for 63,277 shares. Wildcat Cap Mgmt Ltd has 1.08 million shares for 2.45% of their US portfolio. State Board Of Administration Of Florida Retirement Systems accumulated 54,156 shares or 0% of the stock. Alps holds 0% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG) for 50,426 shares. Strs Ohio accumulated 0% or 49,500 shares. The Massachusetts-based State Street has invested 0% in MiMedx Group Inc (NASDAQ:MDXG). Raymond James & Assocs accumulated 0% or 182,108 shares. Proshare Advisors Limited Liability Corporation accumulated 14,738 shares or 0% of the stock. Globeflex L P has invested 0.09% of its portfolio in MiMedx Group Inc (NASDAQ:MDXG). Atlantic Trust Group Inc Ltd Liability accumulated 1.48 million shares or 0.09% of the stock. First Comml Bank Na owns 40,000 shares or 0.06% of their US portfolio. Nationwide Fund Advsr, a Pennsylvania-based fund reported 67,650 shares. Brown Advisory has 0.01% invested in the company for 341,542 shares.
Insider Transactions: Since May 12, 2016, the stock had 4 insider buys, and 3 sales for $394,659 net activity. PETIT PARKER H also bought $139,800 worth of MiMedx Group Inc (NASDAQ:MDXG) on Friday, May 20. $183,018 worth of MiMedx Group Inc (NASDAQ:MDXG) shares were sold by Taylor William Charles.
More notable recent MiMedx Group Inc (NASDAQ:MDXG) news were published by: Streetinsider.com which released: “MiMedx Group (MDXG) Q3 Revenue Tops Expectations” on October 10, 2016, also Prnewswire.com with their article: “MiMedx Announces 2015 Record Results” published on February 23, 2016, Prnewswire.com published: “MiMedx Announces Nationwide Launch of New Ambient Temperature Version of OrthoFlo” on July 25, 2016. More interesting news about MiMedx Group Inc (NASDAQ:MDXG) were released by: Prnewswire.com and their article: “MiMedx Reaffirms Q3 and Full Year 2016 Guidance” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “MiMedx Announces Nationwide Launch of AmnioFillâ„¢” with publication date: September 01, 2016.
MDXG Company Profile
MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Firm operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. The Company’s biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through its donor program, a mother delivering a baby through scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. The Firm processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.